ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Provided By GlobeNewswire
Last update: Jul 21, 2025
Enrollment in FURVENT was completed in Q1 2025
Firmonertinib received FDA Breakthrough Therapy Designation in this patient population
Read more at globenewswire.com
